# GWAS meta-analysis of cerebrospinal fluid Alzheimer's biomarkers reveals loci regulating lipids, brain volume and autophagy.

- **DOI:** [10.1038/s41467-026-71682-8](https://doi.org/10.1038/s41467-026-71682-8)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** A large CSF-biomarker GWAS expands locus discovery, but its causal and mechanistic claims exceed the supporting analyses.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41467-026-71682-8

## Key claims

1. The associated genes are implicated in lipid metabolism independent of APOE, coupled with autophagy and brain volume regulation driven by total tau and phosphorylated tau 181 dysregulation.
   - Support: Tentative
   - Type: Primary finding
   - Basis: mechanistic interpretation relies on exploratory enrichment, gene nomination, and non-significant brain-volume covariance
   - Location: Abstract
2. higher levels of Aβ42 are causally associated with a reduced risk of Alzheimer’s disease
   - Support: Tentative
   - Type: Secondary
   - Basis: causal framing lacks reported sensitivity analyses addressing instrument dominance and possible sample overlap
   - Location: Results, “CSF Aβ42 is causally associated with increased risk of AD”
3. We also demonstrate that these variants have significant association with Alzheimer’s disease risk, disease progression and/or brain amyloidosis.
   - Support: Tentative
   - Type: Secondary
   - Basis: several lookups are nominal and some lead variants show no association with the evaluated phenotypes
   - Location: Abstract

## Strengths

- **Largest CSF biomarker GWAS resource** The analysis combines 18,948 participants from 30 studies, substantially extending the sample sizes described for earlier CSF Aβ42, t-tau, and p-tau181 GWAS.
  - Dimension: contribution
  - Location: Introduction; Methods, “Study design”; Table 1
- **Comprehensive primary GWAS quality controls** The study applies cohort-level biomarker normalization, genotype and imputation QC, relatedness and ancestry filtering, inverse-variance meta-analysis, LDSC checks, and per-locus heterogeneity reporting.
  - Dimension: methodological rigour
  - Location: Methods, “CSF measurement and quality control” through “Meta-analysis and conditional analysis”; Table 2
- **Strong cumulative research trajectory** The study benchmarks against earlier CSF GWAS, replicates established signals, applies MTAG and pleioFDR, and makes phenotype-specific summary statistics available for follow-up.
  - Dimension: application pathway
  - Location: Introduction; Results, “Shared genetic influences across traits”; Figure 2 caption

## Limitations

- **Causal and mechanistic claims overreach** The MR analysis is presented causally without reported leave-one-out or APOE-excluded sensitivity analyses, while pathway and brain-volume interpretations are stronger than the nominal or non-significant evidence supports.
  - Dimension: methodological rigour
  - Location: Results, MR, genetic covariance, and pathway sections; Figures 3C and 4; Discussion
- **Central result labels are inconsistent** The Abstract’s novelty count and BIN1 designation conflict with Table 2 and the Results, and the C16orf95 lead-variant identifier differs between the text and table.
  - Dimension: reporting
  - Location: Abstract; Results, “Meta-analysis replicates previously reported associations”; Table 2
- **Limited replication and population coverage** The novel loci lack independent replication, and the principal analysis is restricted to European ancestry; the non-European comparison includes only 416 participants and is exploratory.
  - Dimension: application pathway
  - Location: Methods, “Study design”; Results, “Cross-ancestry comparisons”; Discussion, limitations paragraph

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - We also demonstrate that these variants have significant association with Alzheimer’s disease risk, disease progression and/or brain amyloidosis: "We also demonstrate that these variants have significant association with Alzheimer's disease risk, disease progression and/or brain amyloidosis." (Abstract) vs "Lead variants on SLCO1A2 and chromosomes 8 loci did not show significant associations with any other phenotypes evaluated." (Results, Significant genetic loci show association with AD risk and progression). The Abstract's unqualified statement about these variants conflicts with the Results' explicit exclusion of SLCO1A2 and the chromosome 8 locus from significant associations with the evaluated AD-related phenotypes. → Not supported by the paper's own data
  - higher levels of Aβ42 are causally associated with a reduced risk of Alzheimer’s disease: "CSF AΒ42 IS CAUSALLY ASSOCIATED WITH INCREASED RISK OF AD" (Results, Mendelian randomization subsection heading) vs "Specifically, the IVW method demonstrated an effect size of -1.806 and a highly significant p-value (p = 1.14×10−16)." (Results, CSF Aβ42 is causally associated with increased risk of AD). The heading says increased AD risk, whereas the reported IVW estimate of -1.806 is negative and is interpreted in the accompanying text as higher Aβ42 reducing AD risk. → Not supported by the paper's own data
  - Minor reporting notes (1):
    - Descriptive: "identify 12 genome-wide significant loci across all three biomarkers, eight of them novel." (Abstract) vs "We identified 12 unique genome-wide significant variants across Aβ42, t-tau, and p-tau181 including one novel association for Aβ42, five for t-tau, and four for p-tau181" (Results, Meta-analysis replicates previously reported associations). Counting distinct regions and rsIDs in Table 2 gives 10 loci and 12 variants, while the trait-specific novelty descriptions identify six novel loci represented by eight distinct variants because GNA12 and MS4A each have different lead variants for the two tau traits. → Changes the size materially
- **Reporting and transparency:** Noted. Table 2 reverses the narrative novelty labels for CR1–Aβ42 and BIN1–Aβ42, and the chromosome 16 lead SNP identifier differs between the table and text.
  - Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: not stated
- **Reference integrity:** Noted
  - 90 references in manuscript
  - 90 of 90 checkable references found in an index
  - 1 DOI points to a different paper:
    - #39 D Z, KS K, TE M, V Y, BM D. Galpha12 directly interacts with PP2A: evidence FOR Galpha12-stimulated PP2A phosphatase activity and dephosphorylation of microtubuleassociated protein, tau - PubMed. The Journal of biological chemistry. 12/31/2004;279(53) (DOI resolves to: “Gα12 Directly Interacts with PP2A” — Zhu, 2004 (Journal of Biological Chemistry)) https://doi.org/10.1074/jbc.C400508200
  - Citation details diverge for 5 references:
    - #1 2022 Alzheimer's disease facts and figures - PubMed. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2022 Apr;18(4) (DOI resolves to: “2022 Alzheimer's disease facts and figures” — 2022 (Alzheimer's &amp; Dementia). Differs from the DOI’s record on: container) https://doi.org/10.1002/alz.12638
    - #26 Corneveaux JJ, Liang WS, Reiman EM, et al. Evidence for an association between KIBRA and late-onset Alzheimer’s disease. Neurobiology of aging. 2008 Sep 13;31(6) (DOI resolves to: “Evidence for an association between KIBRA and late-onset Alzheimer's disease” — Corneveaux, 2010 (Neurobiology of Aging). Differs from the DOI’s record on: year, authors) https://doi.org/10.1016/j.neurobiolaging.2008.07.014
    - #56 M B, L T, I H, et al. Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs - PubMed. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2014 May;10(3) (DOI resolves to: “Design of a comprehensive Alzheimer's disease clinic and research center in Spain to meet critical patient and family needs” — Boada, 2013 (Alzheimer's &amp; Dementia). Differs from the DOI’s record on: container, authors) https://doi.org/10.1016/j.jalz.2013.03.006
    - #57 N V-T, P G, B R-F, et al. Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's continuum - PubMed. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024 Mar;20(3) (DOI resolves to: “Genetic characterization of the ALFA study: Uncovering genetic profiles in the Alzheimer's <i>continuum</i>” — Vilor‐Tejedor, 2023 (Alzheimer's &amp; Dementia). Differs from the DOI’s record on: container, authors) https://doi.org/10.1002/alz.13537
    - #66 S M-G, I dR, I H, et al. Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project - PubMed. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2019 Oct;15(10) (DOI resolves to: “Genome‐wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project” — Moreno‐Grau, 2019 (Alzheimer's &amp; Dementia). Differs from the DOI’s record on: container, authors) https://doi.org/10.1016/j.jalz.2019.06.4950
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
